Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/TNRC6A_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/TNRC6A_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/TNRC6A_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/TNRC6A_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/TNRC6A_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/TNRC6A_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/TNRC6A_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/TNRC6A_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/TNRC6A_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/TNRC6A_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004348725 | Thyroid | ATC | regulation of RNA stability | 97/6293 | 170/18723 | 2.68e-10 | 7.70e-09 | 97 |
GO:006101325 | Thyroid | ATC | regulation of mRNA catabolic process | 95/6293 | 166/18723 | 3.27e-10 | 9.16e-09 | 95 |
GO:004348826 | Thyroid | ATC | regulation of mRNA stability | 90/6293 | 158/18723 | 1.31e-09 | 3.30e-08 | 90 |
GO:003166927 | Thyroid | ATC | cellular response to nutrient levels | 112/6293 | 215/18723 | 1.57e-08 | 3.20e-07 | 112 |
GO:003166827 | Thyroid | ATC | cellular response to extracellular stimulus | 125/6293 | 246/18723 | 1.65e-08 | 3.31e-07 | 125 |
GO:004259424 | Thyroid | ATC | response to starvation | 103/6293 | 197/18723 | 4.59e-08 | 8.31e-07 | 103 |
GO:000926724 | Thyroid | ATC | cellular response to starvation | 85/6293 | 156/18723 | 6.14e-08 | 1.09e-06 | 85 |
GO:0061157110 | Thyroid | ATC | mRNA destabilization | 52/6293 | 84/18723 | 1.01e-07 | 1.70e-06 | 52 |
GO:0061014110 | Thyroid | ATC | positive regulation of mRNA catabolic process | 53/6293 | 87/18723 | 1.63e-07 | 2.61e-06 | 53 |
GO:0031667210 | Thyroid | ATC | response to nutrient levels | 212/6293 | 474/18723 | 2.37e-07 | 3.70e-06 | 212 |
GO:0050779110 | Thyroid | ATC | RNA destabilization | 53/6293 | 88/18723 | 2.75e-07 | 4.20e-06 | 53 |
GO:0000288110 | Thyroid | ATC | nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay | 36/6293 | 56/18723 | 2.57e-06 | 3.00e-05 | 36 |
GO:003424923 | Thyroid | ATC | negative regulation of cellular amide metabolic process | 121/6293 | 273/18723 | 1.36e-04 | 9.57e-04 | 121 |
GO:006021119 | Thyroid | ATC | regulation of nuclear-transcribed mRNA poly(A) tail shortening | 12/6293 | 15/18723 | 3.10e-04 | 1.94e-03 | 12 |
GO:000028919 | Thyroid | ATC | nuclear-transcribed mRNA poly(A) tail shortening | 19/6293 | 29/18723 | 4.39e-04 | 2.62e-03 | 19 |
GO:001714823 | Thyroid | ATC | negative regulation of translation | 107/6293 | 245/18723 | 6.17e-04 | 3.51e-03 | 107 |
GO:0060213111 | Thyroid | ATC | positive regulation of nuclear-transcribed mRNA poly(A) tail shortening | 10/6293 | 13/18723 | 1.77e-03 | 8.71e-03 | 10 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TNRC6A | SNV | Missense_Mutation | novel | c.1531N>C | p.Glu511Gln | p.E511Q | Q8NDV7 | protein_coding | tolerated(0.13) | possibly_damaging(0.837) | TCGA-A1-A0SI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TNRC6A | SNV | Missense_Mutation | novel | c.3425N>G | p.Glu1142Gly | p.E1142G | Q8NDV7 | protein_coding | tolerated(0.11) | benign(0.038) | TCGA-A8-A06R-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | CR |
TNRC6A | SNV | Missense_Mutation | novel | c.847N>A | p.Leu283Ile | p.L283I | Q8NDV7 | protein_coding | tolerated(0.55) | benign(0.003) | TCGA-A8-A097-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
TNRC6A | SNV | Missense_Mutation | | c.3223N>C | p.Asp1075His | p.D1075H | Q8NDV7 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
TNRC6A | SNV | Missense_Mutation | | c.2810C>T | p.Ser937Leu | p.S937L | Q8NDV7 | protein_coding | deleterious(0.03) | benign(0.101) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TNRC6A | SNV | Missense_Mutation | | c.5274N>T | p.Trp1758Cys | p.W1758C | Q8NDV7 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TNRC6A | SNV | Missense_Mutation | | c.1854N>A | p.Asn618Lys | p.N618K | Q8NDV7 | protein_coding | deleterious(0.01) | benign(0.036) | TCGA-AR-A1AH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | | PD |
TNRC6A | SNV | Missense_Mutation | | c.5350N>A | p.Val1784Ile | p.V1784I | Q8NDV7 | protein_coding | deleterious(0) | probably_damaging(0.978) | TCGA-AR-A1AL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | anastrozole | SD |
TNRC6A | SNV | Missense_Mutation | | c.5299N>T | p.Pro1767Ser | p.P1767S | Q8NDV7 | protein_coding | tolerated(0.15) | benign(0.158) | TCGA-B6-A0RG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TNRC6A | SNV | Missense_Mutation | | c.994G>A | p.Glu332Lys | p.E332K | Q8NDV7 | protein_coding | tolerated(0.14) | benign(0.018) | TCGA-GM-A2DH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | CR |